EDAN(SZ:300206) Sou Hu Cai Jing·2025-05-24 12:58Core Viewpoint - The company is focusing on business expansion and operational efficiency to recover from a significant revenue decline in 2024, with optimistic projections for 2025 growth [2][4]. Group 1: Company Performance and Plans - As of May 23, 2025, the company's stock price is 11.6 yuan, down 1.36% from the previous week, with a total market capitalization of 6.724 billion yuan [1]. - The company plans to deepen its domestic market presence and expand internationally, while accelerating the market layout of high-tech products [1]. - The second phase of the industrial building project is expected to be completed by the end of 2025, with the current construction phase involving basement work and mechanical installations [1]. - The profit distribution plan for 2024 has been approved by the shareholders' meeting and will be executed promptly after necessary approvals [1][4]. Group 2: Market Conditions and Challenges - The company experienced an 82% year-on-year revenue decline in 2024 due to industry policy adjustments and economic changes, but is optimistic about domestic sales growth in 2025 [2][4]. - The company has implemented measures to optimize personnel, market strategies, and channel management in response to market changes [2]. - The company has maintained an average of about 10% of its total revenue from the U.S. market, indicating limited impact from international trade challenges [2]. - The global medical device market is projected to grow from $629.2 billion in 2024 to $743.2 billion by 2027, with a compound annual growth rate of 5.71% [3].